Challenges of COVID-19 pandemic for dermatology

Uwe Wollina, Uwe Wollina

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus responsible for the pandemic named coronavirus disease 2019 (COVID-19). The disease causes SARS with a significant morbidity and mortality. We provide a review with a focus on COVID-19 in dermatology. We discuss triage of suspected infectious patients, protection of medical doctors and nurses. We discuss the available data on cutaneous symptoms, although disease-specific symptoms have yet not been observed. COVID-19 is a challenge for the treatment of dermatologic patients, either with severe inflammatory disorders or with skin cancer. The consequences for systemic treatment are obvious but it will be most important to collect the clinical data for a better decision process. Last but not least, education in dermatology for students will not be temporarily possible in the classical settings. COVID-19, although not a skin disease, by itself has an immense impact on dermatology.

Keywords: COVID-19 pandemic; SARS-CoV-2; dermatology.

Conflict of interest statement

The authors declare no potential conflict of interest.

© 2020 Wiley Periodicals LLC.

References

    1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565‐574.
    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med. 2020;382(13):1199‐1207.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;pii:S0140‐6736(20):30566‐30563. 10.1016/S0140-6736(20)30566-3.
    1. Coronavirus COVID‐19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University . . Assessed April 12, 2020.
    1. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID‐19 cases by minimally invasive autopsies [Article in Chinese]. Zhonghua Bing Li Xue Za Zhi. 2020;49:E009. 10.3760/cma.j.cn112151-20200312-00193.
    1. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID‐19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.
    1. Radi G, Diotallevi F, Campanati A, Offidani A. Global coronavirus pandemic (2019‐nCOV): implication for an Italian medium size dermatological clinic of a ii level hospital. J Eur Acad Dermatol Venereol. 2020. 10.1111/jdv.16386.
    1. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246‐251.
    1. Darlenski R, Tsankov N. Covid‐19 pandemic and the skin – what should dermatologists know? Clin Dermatol. 2020. 10.1016/j.clindermatol.2020.03.012.
    1. Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch‐Institut (RKI) . Händehygiene in Einrichtungen des Gesundheitswesens. Bundesgesundheitsbl. 2016;59(9):1189‐1220.
    1. Yan Y, Chen H, Chen L, et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019. Dermatol Ther. 2020;e13310. 10.1111/dth.13310.
    1. Lan J, Song Z, Miao X, et al. Skin damage among healthcare workers managing coronavirus disease‐2019. J Am Acad Dermatol. 2020;pii:S0190‐9622(20):30392‐30393. 10.1016/j.jaad.2020.03.014.
    1. Zheng Y, Lai W. Dermatology staff participate in fight against Covid‐19 in China. J Eur Acad Dermatol Venereol. 2020. 10.1111/jdv.16390.
    1. Yu N, Wu L, Su J, Huang K, Zhao S, Chen X. One more paper towel, longer protection. J Am Acad Dermatol. 2020. 10.1016/j.jaad.2020.03.064.
    1. Wollina U, Hipler U‐C, Nenoff P. Trichobacteriosis, erythrasma and pitted keratolysis—the spectrum of non‐diphtheroid corynebacteria . Rom J Clin Exp Dermatol. 2017;2(4):64‐67.
    1. Lin P, Zhu S, Huang Y, et al. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. Br J Dermatol. 2020. 10.1111/bjd.19089.
    1. Cavanagh G, Wambier C. Rational hand hygiene during COVID‐19 pandemic. J Am Acad Dermatol. 2020. 10.1016/j.jaad.2020.03.090.
    1. Bauer A, Rönsch H, Elsner P, et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev. 2018;4:CD004414.
    1. Jakhar D, Kaur I, Kaul S. Art of performing dermoscopy during the times of coronavirus disease (COVID‐19): simple change in approach can save the day! J Eur Acad Dermatol Venereol. 2020. 10.1111/jdv.16412.
    1. Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): An interplay among drugs, viruses, and immune system. Int J Mol Sci. 2017;18(6):pii:E1243.
    1. Drago F, Ciccarese G, Gasparini G, et al. Contemporary infectious exanthems: an update. Future Microbiol. 2017;12:171‐193.
    1. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020. 10.1111/all.14238.
    1. Recalcati S. Cutaneous manifestations in COVID‐19: a first perspective. J Eur Acad Dermatol Venereol. 2020. 10.1111/jdv.16387.
    1. Lee C‐H. Role of dermatologists in the uprising of the novel corona virus (COVID‐19): perspectives and opportunities. Dermatol Sin. 2020;38(1):1‐2.
    1. Wollina, U. , & Nowak, A . (2012). Dermatology in the intensive care unit. Our Dermatol Online, 3(4), 298–303.
    1. Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics of 7 patients with critical COVID‐2019 pneumonia and acro‐ischemia. Zhonghua Xue Ye Xue Za Zhi. 2020;41:E006.
    1. Wang C, Rademaker M, Baker C, Foley P. COVID‐19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement. Australas J Dermatol. 2020. 10.1111/ajd.13313.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019‐nCoV lung injury. Lancet. 2020;395(10223):473‐475.
    1. Baysham AM, Feldman SR. Should patients stop their biologic treatment during the COVID‐19 pandemic. J Dermatol Treat. 2020;1‐2. 10.1080/09546634.2020.1742438.
    1. Lebwohl M, Rivera‐Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID‐19? J am Acad Dermatol. 2020;S0190‐9622(20)30445‐X. 10.1016/j.jaad.2020.03.031.
    1. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate‐to‐severe plaque psoriasis (UltIMMa‐1 and UltIMMa‐2): results from two double‐blind, randomised, placebo‐controlled and ustekinumab‐controlled phase 3 trials. Lancet. 2018;392(10148):650‐661.
    1. Camus, P. (2019). The drug‐induced respiratory disease website, Pneumotox Online V2.2. . Assessed April 7, 2020.
    1. Gurczynski SJ, Moore BB. IL‐17 in the lung: the good, the bad, and the ugly. Am J Physiol Lung Cell Mol Physiol. 2018;314(1):L6‐L16.
    1. Liao HH, Wang YC, Chen MC, et al. Down‐regulation of granulocyte‐macrophage colony‐stimulating factor by 3C‐like proteinase in transfected A549 human lung carcinoma cells. BMC Immunol. 2011;12:16.
    1. Law HK, Cheung CY, Ng HY, et al. Chemokine up‐regulation in SARS‐coronavirus‐infected, monocyte‐derived human dendritic cells. Blood. 2005;106(7):2366‐2374.
    1. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID‐19 in Wuhan, China. Clin Infect Dis. 2020. 10.1093/cid/ciaa248.
    1. Sarzi‐Puttini P, Giorgi V, Sirotti S, et al. COVID‐19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337‐342.
    1. Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio. 2013;4(3):e00165‐13.
    1. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID‐19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020;e13298. 10.1111/dth.13298.
    1. Wollenberg A, Flohr C, Simon D, et al. European task force on atopic dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2)‐infection and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020. 10.1111/jdv.16411.
    1. Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID‐19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020;18:366‐369. 10.6004/jnccn.2020.7560.
    1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS‐CoV‐2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335‐337.
    1. Reinholz M, French LE. Medical education and care in dermatology during the SARS‐CoV2 pandemia: challenges and chances. J Eur Acad Dermatol Venereol. 2020. 10.1111/jdv.16391.
    1. Weston S, Frieman MB. COVID‐19: knowns, unknowns, and questions. mSphere. 2020;5(2):pii:e00203‐20.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren